Core Insights - Alnylam Pharmaceuticals reported fourth-quarter 2025 adjusted earnings of $1.25 per share, exceeding the Zacks Consensus Estimate of $1.16, compared to adjusted earnings of 6 cents in the same quarter last year [1] - Total revenues for the quarter were $1.10 billion, falling short of the Zacks Consensus Estimate of $1.14 billion, but representing an 85% year-over-year increase from $593.2 million [2] Financial Performance - Net product revenues reached $994.7 million, marking a 121% increase year over year, driven by strong demand for Amvuttra and other marketed drugs [3] - Net revenues from collaborators were $40.9 million, a 62% decrease from the previous year, primarily due to the absence of revenues from Novartis in the reported quarter [4] - Royalty revenues increased by 73% year over year to $61.4 million [5] Product Performance - Amvuttra generated sales of $826.6 million, up 189% year over year, although it missed the Zacks Consensus Estimate of $837.2 million [8] - Givlaari sales were $86.8 million, reflecting a 34% year-over-year increase and exceeding the Zacks Consensus Estimate of $79.7 million [9] - Oxlumo recorded sales of $49.6 million, a 14% increase year over year, but fell short of the Zacks Consensus Estimate of $55.2 million [9] Guidance and Future Outlook - For 2026, Alnylam expects net product revenues between $4.9 billion and $5.3 billion, indicating a year-over-year growth of 64-77% at constant exchange rates [17] - The company anticipates net revenues from collaborations and royalties to be in the range of $400 million to $500 million, with adjusted R&D and SG&A expenses projected between $2.7 billion and $2.8 billion [17] Overall Assessment - Alnylam's fourth-quarter results were mixed, with earnings surpassing estimates but revenues missing expectations, likely due to high market expectations rather than a decline in demand [18] - The significant year-over-year revenue growth was primarily driven by strong sales of Amvuttra, supported by recent label expansions [19]

Core Insights - Alnylam Pharmaceuticals will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:00 am PT [1] - The company plans to unveil its new five-year strategy aimed at guiding its next phase of growth [1] - An update on unaudited fourth quarter and full year 2025 global net product revenues will be shared, along with an outlook for 2026 product sales [1] Company Overview - Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, focusing on innovative medicines for rare and prevalent diseases with unmet needs [2] - The company has developed commercial RNAi therapeutic products including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, and collaborates with partners like Novartis and Sanofi for additional products [2] - Alnylam has a robust pipeline of investigational medicines, with multiple candidates in late-stage development [2] Strategic Vision - The company is executing its "5Alnylam Px25" strategy to deliver transformative medicines for both rare and common diseases [2] - Alnylam aims to benefit patients globally through sustainable innovation and exceptional financial performance, establishing a leading profile in the biotech industry [2]

Core Insights - Alnylam Pharmaceuticals' primary revenue driver is its newest drug, Amvuttra, approved for treating hATTR amyloidosis and ATTR-CM, with strong uptake from new patients and switches from Onpattro [1][10] Product Portfolio - Alnylam markets several products in rare disease and cardiovascular markets, contributing incremental revenues to the top line [2] - Givlaari is approved for acute hepatic porphyria in adults and adolescents, with strong uptake and plans for regulatory submissions in additional regions through 2025 [3] - Oxlumo is approved for primary hyperoxaluria type 1, with an expanded label for lowering urinary and plasma oxalate levels, enhancing its growth potential [4] - Leqvio, in collaboration with Novartis, treats hypercholesterolemia and has an expanded label for high-risk cardiovascular patients, generating royalties for Alnylam [5] Financial Performance - In the first half of 2025, Alnylam generated $236.8 million in net product revenues from its rare disease portfolio, reflecting a 16% year-over-year increase, with expectations for sustained growth and diversified revenue streams [6][10] Competitive Landscape - Amvuttra faces increasing competition in the ATTR-CM market from therapies like Pfizer's Vyndaqel/Vyndamax and BridgeBio's Attruby, which are already approved and competing for market share [7] - Pfizer's Vyndaqel family generated $3.1 billion in revenues in the first half of 2025, a 27% increase year-over-year, driven by rising diagnosis and treatment rates [8] - BridgeBio's Attruby, approved in late 2024, generated $108.2 million in sales in the first half of 2025, with significant uptake reported [9]

Core Viewpoint - Novartis has received FDA approval for an updated label for Leqvio® (inclisiran), allowing its use as a monotherapy to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, alongside diet and exercise [1][2][3] Group 1: Product Information - Leqvio is now indicated for use as a standalone treatment, removing the previous requirement for combination with statin therapy [3] - The updated label specifies "hypercholesterolemia" instead of "primary hyperlipidemia," focusing on LDL-C reduction [3] - Leqvio is administered twice a year by healthcare providers, which may enhance patient adherence and long-term management of LDL-C levels [2][8] Group 2: Market Need and Impact - Up to 80% of patients with atherosclerotic cardiovascular disease (ASCVD) in the US do not achieve the recommended LDL-C target of less than 70 mg/dL, highlighting a significant unmet medical need [2][8] - The 2025 ACC/AHA guidelines recommend more aggressive treatment strategies to meet LDL-C targets, further emphasizing the importance of Leqvio's new indication [2][8] Group 3: Company Background - Novartis has global rights to develop, manufacture, and commercialize Leqvio through a collaboration with Alnylam Pharmaceuticals, a leader in RNAi therapeutics [4] - The company aims to address critical challenges in cardiovascular disease management and improve patient outcomes through innovative treatments [10][11]

Core Viewpoint - Alnylam Pharmaceuticals reported better-than-expected financial results for Q1 2025, with adjusted losses narrower than estimates and significant revenue growth driven by strong product sales, particularly for Amvuttra [1][2][16]. Financial Performance - The company reported total revenues of $594.2 million, exceeding the Zacks Consensus Estimate of $588.2 million, and reflecting a 20% year-over-year increase [2]. - Net product revenues reached $468.5 million, up 28% year-over-year, primarily due to increased demand for Amvuttra, Givlaari, and Oxlumo [2][6]. - Net revenues from collaborators were $99.2 million, down 16% from the previous year, largely due to a prior milestone payment from Roche [3]. Product Sales - Amvuttra generated sales of $310 million, a 59% increase year-over-year, and surpassed estimates [6]. - Givlaari recorded sales of $67 million, a 15% increase year-over-year, but slightly missed estimates [7]. - Oxlumo's sales were $42.1 million, remaining flat year-over-year and missing estimates [7]. Expenses and Cash Position - Adjusted R&D expenses were approximately $241.3 million, remaining stable year-over-year [10]. - Adjusted SG&A expenses increased by 12% to $207 million, driven by marketing efforts for Amvuttra [11]. - Cash, cash equivalents, and marketable securities totaled $2.63 billion as of March 31, 2025, down from $2.69 billion at the end of 2024 [11]. Guidance and Collaborations - The company reiterated its 2025 financial guidance, expecting net product revenues between $2.05 billion and $2.25 billion, and collaboration revenues between $650 million and $750 million [12]. - Alnylam is advancing several collaborations, including with Regeneron and Roche, which are expected to enhance its product pipeline and revenue streams [13][14][17]. Market Performance - Year-to-date, Alnylam's stock has gained 8.4%, outperforming the industry, which has seen a decline of 1.8% [8].